Clinical Trial Update: Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing TAK-659 in adults with relapsed or refractory acute myeloid leukemia (AML) has been terminated; results were posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• TAK-659 (TAK-659)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Acute Myelogenous Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-05-11